Tuberculosis Research and Treatment / 2017 / Article / Tab 2

Review Article

Nanotechnology-Based Approach in Tuberculosis Treatment

Table 2

Therapeutic efficacy of nanoparticle-based antitubercular drug delivery systems.

Delivery systemDrug : carrier ratioUse of organic solvents Drug encapsulation efficiencyMode of deliveryAnimal modelDuration of sustained drug release (days)Sterilizing effect in lungs and spleenReferences
PlasmaOrgan

Synthetic
(i) PLG nanoparticles1 : 1 for each drugDichloromethane60–70%Oral 
Aerosol 
Subcutaneous
Mice 
Guinea pigs 
Mice
6–8 
6–8 
32
9–11 
9–11 
36
5 doses every 10 d 
5 doses every 10 d 
Single injection
[14, 15] 
[16] 
[17]
(ii) Lectin functionalized PLG nanoparticles1 : 1 for each drugDichloromethane60–70%Oral 
Aerosol
Guinea pigs 
Guinea pigs
6–14 
6–14
15 
15
3 doses fortnightly 
3 doses fortnightly
[14] 
[15]

Natural
(i) LiposomesRIF 0.22 : 1 
INH 0.14 : 1
Chloroform, methanol35–45% 
8–12%
Intravenous 
Aerosol
Mice, Guinea pigs 
Guinea pigs
5–7 
2
7 
5
2 doses every week  
single dose every 5–7 days
[15, 18] 
[19]
(ii) Solid lipid nanoparticles1 : 1 for each drugAcetone, ethanol40–50%Oral 
Aerosol
Mice 
Guinea pigs
8 
5
10 
7
5 doses every 10 d
7 doses weekly
[20] 
[21]
(iii) Alginate nanoparticles7.5 : 1 for each drugNo70–80%Oral 
Aerosol
Mice/Guinea pigs 
Guinea pigs
8–11 
8–11
15 
15
3 doses fortnightly 
3 doses fortnightly
[22] 
[22]

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.